 In a recent trial 2, Inclusion of low-dose prednisone from the start into a two-year MTX-based tight control treatment strategy for early RA increases both effectiveness i.e. disease activity variables and outcome i.e. erosive joint damage without increasing toxicity. It also reduces the need for early treatment with biologicals. 